Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease
C Zheng - Current opinion in lipidology, 2014 - journals.lww.com
Current opinion in lipidology, 2014•journals.lww.com
Recent data further strengthen the theory that apoCIII exerts strong atherogenic functions
through both indirect and direct mechanisms. Encouraging results from early stage clinical
trials demonstrate that modulating apoCIII per se is a novel and potent therapeutic approach
to managing dyslipidemia and cardiovascular disease risk.
through both indirect and direct mechanisms. Encouraging results from early stage clinical
trials demonstrate that modulating apoCIII per se is a novel and potent therapeutic approach
to managing dyslipidemia and cardiovascular disease risk.
Summary
Recent data further strengthen the theory that apoCIII exerts strong atherogenic functions through both indirect and direct mechanisms. Encouraging results from early stage clinical trials demonstrate that modulating apoCIII per se is a novel and potent therapeutic approach to managing dyslipidemia and cardiovascular disease risk.
Lippincott Williams & Wilkins